The long decline - i'm a jew - Google
To see the state to which things have fallen, one need only compare Fowler with a modern composition text and a modern prescriptive grammarian on a vexed point of grammar -- the problem of which pronoun to use with an antecedent like each or anyone . Here is Fowler: Each & the rest are all singular; that is undisputed; in a perfect language there would exist pronouns & possessives that were of as doubtful gender as they & yet were, like them, singular; ., it would have words meaning him-or-her, himself-or-herself, his-or-her. But just as French lacks our power of distinguishing (without additional words) between his, her, and its, so we lack the French power of saying in one word his-or-her. There are three makeshifts: -- A, as anybody can see for himself or herself; B} , as anybody can see for themselves; & C , as anybody can see for himself. No-one who can help it chooses A; it is correct, & is sometimes necessary, but it is so clumsy as to be ridiculous except when explicitness is urgent. . B is the popular solution; it sets the literary man's teeth on edge & he exerts himself to give the same meaning in some entirely different way if he is not prepared, as he usually is, to risk C; but it should be recorded that the OED . . refrains from any word of condemnation. C is here recommended. It involves the convention that where the matter of sex is not conspicuous or important he and his shall be allowed to represent a person instead of a man, or say a man (homo) instead of a man (vir). Whether that . . is an arrogant demand on the part of male England, everyone must decide for himself (or for himself or herself, or for themselves).
People want to be a part of something that makes a difference. They desire to be involved in something bigger than themselves.
Your thank you note is also a great opportunity to expand your network. Feel free to mention your LinkedIn page, your website, or other professional pages, and ask them to stay in touch. You might as well make another ally.
If you want to get even more from TED, like the ability to save talks to watch later, sign up for a TED account now .
Americans only drank slightly less beer, the most common form of alcohol consumption at that time, between 1990 and 2000. But it was enough for the Brennan Center to attribute to it a percent drop in crime during the 1990s.
You may recall friends and family dumping buckets of ice on their head to raise funds for treating amyotrophic lateral sclerosis (ALS), a debilitating neuro-degenerative disease.
Current treatments are able to slow ALS’ progression but fail to maintain or restore motor movement. Now, multiple clinical trials conducted by an Israeli firm, Brainstorm Cell Therapeutics, show a first-ever reversal in expected decline for patients, likely to transform how we treat ALS.
Be the first to know - Join our Facebook page.
“We showed a very strong improvement when we compare pre-treatment to post-treatment in the patients that were treated,” said Chaim Lebovits, CEO of Brainstorm, referring to the company’s advanced stem cell therapy treatment. “It means that it’s not even a slowdown of the disease, or a halt, but it’s a reversal of it. It’s unheard of in ALS, if we replicate this in a third trial.”
BrainStorm announced on Monday that its first patients had enrolled in a phase three clinical trial for its treatment of ALS at two American hospitals. The research will occur at Massachusetts General Hospital, UC Irvine Medical Center in California and the Mayo Clinic in Minnesota — and it will include some 200 patients, half of whom will be given a placebo.
The company expects that if the stage three trial goes well, that the US Food and Drug Administration may give regulatory approval for mass use among doctors and patients. The trial will be measured by the ALSFR-S score responder analysis and final data is expected by 2019.
BrainStorm’s first two clinical trials of its stem cell therapy treatment, called NurOwn, were conducted at Jerusalem’s Hadassah hospital and also in the United States.
During the treatment process, doctors extract cells from the bone marrow of from patients with ALS, and the cells are multiplied and matured, then prepared for injection back into the patient. During the maturation process, the cells from the bone marrow are manipulated into behaving like brain cells, in that they produce materials that are the building blocks of the brain. When these modified cells are put back in patients, the building blocks circulate in the spinal fluid and help repair the damaged brain.
Since the cells are taken directly from the patient, that avoids the need for patients to be immunosuppressed so their bodies don’t attack a foreign substance.
“This is unprecedented, I’m not aware of another treatment program where the potential to alter or improve ALS is as great. We’re very encouraged by the promising results seen so far, and the changes in biomarkers that measure the building blocks of the brain — they suggest that the delivery of these substances is having an effect… we’re confident that we’re on the right track,” said Ralph Kern, MD, Brainstorm’s Chief Operating Officer and Chief Medical Officer.
For patients suffering from ALS, the disease affects the brain’s motor system, or what controls muscle movement and muscle contraction. Patients who are diagnosed with ALS have, on average, some 30 months to live, and famed British astrophysicist Stephen Hawking who suffers from the disease has been an outlier when it comes to longevity.
Because the motor system controls all of our muscles, it can affect our arms and legs, it can also affect our swallowing and our breathing. And it’s the loss of our ability to swallow and breathe that is the most dangerous,” said Kern.
Founded in 2006, the Israeli start-up is based in the central town of Petah Tikva, employs some 22 people, and it has raised some $70 million. The phase three clinical trial received a $16 million grant from the California Institute for Regenerative Medicine, which specializes in stem cell therapy. The company also previously benefited from funding provided by the Israel Innovation Authority.
The stem cell therapy was developed at Tel Aviv University and licensed through Ramot, the university’s technology transfer arm. The university will receive some royalties from the treatment.
Commonly known as Lou Gehrig’s Disease in the United States, ALS is diagnosed in thousands of people worldwide each year.
“We’re trying to change the course of ALS,” Lebovits said. "Brainstorm plans to quickly advance the phase 3 trial to… bring much needed hope to ALS patients and their families.”
The long-term trend is even more encouraging: On average, only about half as many police are murdered every year now, as compared with the 1970s. Stoughton says some of that improvement is probably due to better training, better gear and radically improved trauma care for cops who are shot.
The Roman Empire reached its greatest geographical extent under Trajan (emperor 98–117), who ruled a prosperous state that stretched from Mesopotamia to the Atlantic. The Empire had large numbers of trained, supplied, and disciplined soldiers, as well as a comprehensive civil administration based in thriving cities with effective control over public finances. Among its literate elite it had ideological legitimacy as the only worthwhile form of civilization and a cultural unity based on comprehensive familiarity with Greek and Roman literature and rhetoric. The Empire's power allowed it to maintain extreme differences of wealth and status (including slavery on a large scale),  and its wide-ranging trade networks permitted even modest households to use goods made by professionals far away.